# Cryo Cell International Inc: financial statements, quarterly

CCEL · NYSE · CIK 862692 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Nov 30

Pages: [Overview](/companies/ccel.md) · [Financials](/companies/ccel/financials.md) · [Filings](/companies/ccel/filings.md) · [Insiders](/companies/ccel/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/ccel/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2023 (2023-11-30) | Q1 FY2024 (2024-02-29) | Q2 FY2024 (2024-05-31) | Q3 FY2024 (2024-08-31) | Q4 FY2024 (2024-11-30) | Q1 FY2025 (2025-02-28) | Q2 FY2025 (2025-05-31) | Q3 FY2025 (2025-08-31) | Q4 FY2025 (2025-11-30) | Q1 FY2026 (2026-02-28) | Q2 FY2026 (2026-05-31) | Q3 FY2026 (2026-08-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [7.9 d](/filings/0000950170-25-030138.md) | [7.9](/filings/0000950170-25-053767.md) | [8.0](/filings/0000950170-25-095916.md) | [8.1](/filings/0001193125-25-240385.md) | [8.0 d](/filings/0001193125-26-083096.md) | [8.0](/filings/0001193125-26-155057.md) | [7.9](/filings/0001193125-26-304834.md) | [7.8](/filings/0001193125-26-419156.md) | [7.8 d](/filings/0001193125-26-083096.md) | [7.7](/filings/0001193125-26-155057.md) | [7.8](/filings/0001193125-26-304834.md) | [7.8](/filings/0001193125-26-419156.md) |
| Cost of revenue | $m | [2.0 d](/filings/0000950170-25-030138.md) | [2.1](/filings/0000950170-25-053767.md) | [2.0](/filings/0000950170-25-095916.md) | [2.1](/filings/0001193125-25-240385.md) | [1.6 d](/filings/0001193125-26-083096.md) | [2.0](/filings/0001193125-26-155057.md) | [1.9](/filings/0001193125-26-304834.md) | [1.8](/filings/0001193125-26-419156.md) | [1.7 d](/filings/0001193125-26-083096.md) | [1.7](/filings/0001193125-26-155057.md) | [1.7](/filings/0001193125-26-304834.md) | [1.6](/filings/0001193125-26-419156.md) |
| Research and development | $m | [0.4 d](/filings/0000950170-25-030138.md) | [0.5](/filings/0000950170-25-053767.md) | [0.2](/filings/0000950170-25-095916.md) | [0.2](/filings/0001193125-25-240385.md) | [0.3 d](/filings/0001193125-26-083096.md) | [0.1](/filings/0001193125-26-155057.md) | [0.1](/filings/0001193125-26-304834.md) | [0.1](/filings/0001193125-26-419156.md) | [0.1 d](/filings/0001193125-26-083096.md) | [0.1](/filings/0001193125-26-155057.md) | [0.1](/filings/0001193125-26-304834.md) | [0.1](/filings/0001193125-26-419156.md) |
| Selling, general and administrative | $m | [5.4 d](/filings/0000950170-25-030138.md) | [4.4](/filings/0000950170-25-053767.md) | [4.0](/filings/0000950170-25-095916.md) | [4.2](/filings/0001193125-25-240385.md) | [6.0 d](/filings/0001193125-26-083096.md) | [4.6](/filings/0001193125-26-155057.md) | [4.3](/filings/0001193125-26-304834.md) | [3.9](/filings/0001193125-26-419156.md) | [5.4 d](/filings/0001193125-26-083096.md) | [5.0](/filings/0001193125-26-155057.md) | [4.6](/filings/0001193125-26-304834.md) | [3.8](/filings/0001193125-26-419156.md) |
| Operating income | $m | [(16.2) d](/filings/0000950170-25-030138.md) | [0.8](/filings/0000950170-25-053767.md) | [1.4](/filings/0000950170-25-095916.md) | [1.4](/filings/0001193125-25-240385.md) | [(0.1) d](/filings/0001193125-26-083096.md) | [1.1](/filings/0001193125-26-155057.md) | [1.5](/filings/0001193125-26-304834.md) | [1.9](/filings/0001193125-26-419156.md) | [(4.0) d](/filings/0001193125-26-083096.md) | [0.8](/filings/0001193125-26-155057.md) | [1.2](/filings/0001193125-26-304834.md) | [2.2](/filings/0001193125-26-419156.md) |
| Interest expense | $m | [(0.2) d](/filings/0000950170-25-030138.md) | [0.3](/filings/0000950170-25-053767.md) | [0.3](/filings/0000950170-25-095916.md) | [0.5](/filings/0001193125-25-240385.md) | [0.7 d](/filings/0001193125-26-083096.md) | [0.5](/filings/0001193125-26-155057.md) | [0.6](/filings/0001193125-26-304834.md) | [0.5](/filings/0001193125-26-419156.md) | [0.5 d](/filings/0001193125-26-083096.md) | [0.5](/filings/0001193125-26-155057.md) | [0.4](/filings/0001193125-26-304834.md) | [0.4](/filings/0001193125-26-419156.md) |
| Income tax | $m | [(4.8) d](/filings/0000950170-25-030138.md) | [0.2](/filings/0000950170-25-053767.md) | [0.8](/filings/0000950170-25-095916.md) | [0.3](/filings/0001193125-25-240385.md) | [1.0 d](/filings/0001193125-26-083096.md) | [0.3](/filings/0001193125-26-155057.md) | [0.2](/filings/0001193125-26-304834.md) | [0.4](/filings/0001193125-26-419156.md) | [(0.8) d](/filings/0001193125-26-083096.md) | [0.0](/filings/0001193125-26-155057.md) | [0.3](/filings/0001193125-26-304834.md) | [0.6](/filings/0001193125-26-419156.md) |
| Net income | $m | [(11.2) d](/filings/0000950170-25-030138.md) | [0.6](/filings/0000950170-25-053767.md) | [0.7](/filings/0000950170-25-095916.md) | [1.1](/filings/0001193125-25-240385.md) | [(1.9) d](/filings/0001193125-26-083096.md) | [0.3](/filings/0001193125-26-155057.md) | [0.4](/filings/0001193125-26-304834.md) | [0.7](/filings/0001193125-26-419156.md) | [(3.8) d](/filings/0001193125-26-083096.md) | [0.0](/filings/0001193125-26-155057.md) | [0.6](/filings/0001193125-26-304834.md) | [1.3](/filings/0001193125-26-419156.md) |
| Diluted EPS | $ per share | not reported | [0.07](/filings/0000950170-25-053767.md) | [0.08](/filings/0000950170-25-095916.md) | [0.13](/filings/0001193125-25-240385.md) | not reported | [0.03](/filings/0001193125-26-155057.md) | [0.04](/filings/0001193125-26-304834.md) | [0.09](/filings/0001193125-26-419156.md) | not reported | [0.01](/filings/0001193125-26-155057.md) | [0.07](/filings/0001193125-26-304834.md) | [0.16](/filings/0001193125-26-419156.md) |
| Basic EPS | $ per share | not reported | [0.07](/filings/0000950170-25-053767.md) | [0.08](/filings/0000950170-25-095916.md) | [0.13](/filings/0001193125-25-240385.md) | not reported | [0.03](/filings/0001193125-26-155057.md) | [0.04](/filings/0001193125-26-304834.md) | [0.09](/filings/0001193125-26-419156.md) | not reported | [0.01](/filings/0001193125-26-155057.md) | [0.07](/filings/0001193125-26-304834.md) | [0.16](/filings/0001193125-26-419156.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-11-30) | Q1 FY2024 (2024-02-29) | Q2 FY2024 (2024-05-31) | Q3 FY2024 (2024-08-31) | FY2024 (2024-11-30) | Q1 FY2025 (2025-02-28) | Q2 FY2025 (2025-05-31) | Q3 FY2025 (2025-08-31) | FY2025 (2025-11-30) | Q1 FY2026 (2026-02-28) | Q2 FY2026 (2026-05-31) | Q3 FY2026 (2026-08-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [0.4](/filings/0000950170-25-030138.md) | [0.2](/filings/0000950170-24-044493.md) | [0.5](/filings/0000950170-24-083637.md) | [0.2](/filings/0000950170-24-114762.md) | [0.6](/filings/0001193125-26-083096.md) | [0.2](/filings/0000950170-25-053767.md) | [0.1](/filings/0000950170-25-095916.md) | [0.3](/filings/0001193125-25-240385.md) | [0.3](/filings/0001193125-26-419156.md) | [0.2](/filings/0001193125-26-155057.md) | [0.5](/filings/0001193125-26-304834.md) | [1.4](/filings/0001193125-26-419156.md) |
| Current assets | $m | [9.5](/filings/0000950170-25-030138.md) | [9.5](/filings/0000950170-24-044493.md) | [10.2](/filings/0000950170-24-083637.md) | [10.7](/filings/0000950170-24-114762.md) | [12.6](/filings/0001193125-26-083096.md) | [12.5](/filings/0000950170-25-053767.md) | [13.1](/filings/0000950170-25-095916.md) | [11.7](/filings/0001193125-25-240385.md) | [11.8](/filings/0001193125-26-419156.md) | [11.1](/filings/0001193125-26-155057.md) | [11.3](/filings/0001193125-26-304834.md) | [13.2](/filings/0001193125-26-419156.md) |
| Total assets | $m | [64.7](/filings/0000950170-25-053767.md) | [61.7](/filings/0000950170-24-044493.md) | [62.6](/filings/0000950170-24-083637.md) | [62.9](/filings/0000950170-24-114762.md) | [64.7](/filings/0001193125-26-083096.md) | [64.4](/filings/0000950170-25-053767.md) | [64.4](/filings/0000950170-25-095916.md) | [63.2](/filings/0001193125-25-240385.md) | [61.7](/filings/0001193125-26-419156.md) | [60.9](/filings/0001193125-26-155057.md) | [60.7](/filings/0001193125-26-304834.md) | [62.3](/filings/0001193125-26-419156.md) |
| Current liabilities | $m | [20.9](/filings/0000950170-25-030138.md) | [19.4](/filings/0000950170-24-044493.md) | [19.4](/filings/0000950170-24-083637.md) | [17.4](/filings/0000950170-24-114762.md) | [21.6](/filings/0001193125-26-083096.md) | [21.7](/filings/0000950170-25-053767.md) | [21.8](/filings/0000950170-25-095916.md) | [18.5](/filings/0001193125-25-240385.md) | [19.8](/filings/0001193125-26-419156.md) | [17.8](/filings/0001193125-26-155057.md) | [15.9](/filings/0001193125-26-304834.md) | [15.3](/filings/0001193125-26-419156.md) |
| Total liabilities | $m | [72.3](/filings/0000950170-25-030138.md) | [72.0](/filings/0000950170-24-044493.md) | [73.3](/filings/0000950170-24-083637.md) | [72.5](/filings/0000950170-24-114762.md) | [77.9](/filings/0001193125-26-083096.md) | [79.0](/filings/0000950170-25-053767.md) | [80.0](/filings/0000950170-25-095916.md) | [78.0](/filings/0001193125-25-240385.md) | [80.3](/filings/0001193125-26-419156.md) | [79.3](/filings/0001193125-26-155057.md) | [78.5](/filings/0001193125-26-304834.md) | [78.7](/filings/0001193125-26-419156.md) |
| Long-term debt | $m | [8.6](/filings/0000950170-25-030138.md) | [8.6](/filings/0000950170-24-044493.md) | [8.5](/filings/0000950170-24-083637.md) | [8.5](/filings/0000950170-24-114762.md) | [8.5](/filings/0001193125-26-083096.md) | [8.5](/filings/0000950170-25-053767.md) | [8.4](/filings/0000950170-25-095916.md) | [8.4](/filings/0001193125-25-240385.md) | [8.4](/filings/0001193125-26-419156.md) | [8.3](/filings/0001193125-26-155057.md) | [8.3](/filings/0001193125-26-304834.md) | [8.2](/filings/0001193125-26-419156.md) |
| Shareholders' equity | $m | [(11.0)](/filings/0001193125-26-083096.md) | [(10.3)](/filings/0000950170-25-095916.md) | [(10.7)](/filings/0001193125-25-240385.md) | [(9.6)](/filings/0001193125-25-240385.md) | [(13.2)](/filings/0001193125-26-419156.md) | [(14.7)](/filings/0001193125-26-304834.md) | [(15.6)](/filings/0001193125-26-419156.md) | [(14.8)](/filings/0001193125-26-419156.md) | [(18.6)](/filings/0001193125-26-419156.md) | [(18.4)](/filings/0001193125-26-304834.md) | [(17.8)](/filings/0001193125-26-419156.md) | [(16.4)](/filings/0001193125-26-419156.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q4 FY2023 (2023-11-30) | Q1 FY2024 (2024-02-29) | Q2 FY2024 (2024-05-31) | Q3 FY2024 (2024-08-31) | Q4 FY2024 (2024-11-30) | Q1 FY2025 (2025-02-28) | Q2 FY2025 (2025-05-31) | Q3 FY2025 (2025-08-31) | Q4 FY2025 (2025-11-30) | Q1 FY2026 (2026-02-28) | Q2 FY2026 (2026-05-31) | Q3 FY2026 (2026-08-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [3,344 d](/filings/0000950170-25-030138.md) | [(357)](/filings/0000950170-25-053767.md) | [1,773 d](/filings/0000950170-25-095916.md) | [2,437 d](/filings/0001193125-25-240385.md) | [2,157 d](/filings/0001193125-26-083096.md) | [954](/filings/0001193125-26-155057.md) | [707 d](/filings/0001193125-26-304834.md) | [2,537 d](/filings/0001193125-26-419156.md) | [1,281 d](/filings/0001193125-26-083096.md) | [652](/filings/0001193125-26-155057.md) | [1,846 d](/filings/0001193125-26-304834.md) | [1,142 d](/filings/0001193125-26-419156.md) |
| Capital expenditure | $k | [1,715 d](/filings/0000950170-25-030138.md) | [458](/filings/0000950170-25-053767.md) | [1,752 d](/filings/0000950170-25-095916.md) | [186 d](/filings/0001193125-25-240385.md) | [8.3 d](/filings/0001193125-26-083096.md) | [62.1](/filings/0001193125-26-155057.md) | [62.4 d](/filings/0001193125-26-304834.md) | [38.8 d](/filings/0001193125-26-419156.md) | [67.2 d](/filings/0001193125-26-083096.md) | [67.1](/filings/0001193125-26-155057.md) | [32.7 d](/filings/0001193125-26-304834.md) | [102 d](/filings/0001193125-26-419156.md) |
| Dividends paid | $k | not reported | [0.0](/filings/0000950170-25-053767.md) | [0.0 d](/filings/0000950170-25-095916.md) | [0.0 d](/filings/0001193125-25-240385.md) | [2,021 d](/filings/0001193125-26-083096.md) | [2,021](/filings/0001193125-26-155057.md) | [1,211 d](/filings/0001193125-26-304834.md) | [0.0 d](/filings/0001193125-26-419156.md) | [0.0 d](/filings/0001193125-26-083096.md) | [0.0](/filings/0001193125-26-155057.md) | [0.0 d](/filings/0001193125-26-304834.md) | [0.0 d](/filings/0001193125-26-419156.md) |
| Share repurchases | $k | [0.0 d](/filings/0000950170-25-030138.md) | [170](/filings/0000950170-25-053767.md) | [1,237 d](/filings/0000950170-25-095916.md) | [16.4 d](/filings/0001193125-25-240385.md) | [0.0 d](/filings/0001193125-26-083096.md) | [0.0](/filings/0000950170-25-053767.md) | [88.6 d](/filings/0001193125-26-304834.md) | [80.9 d](/filings/0001193125-26-419156.md) | [0.0 d](/filings/0001193125-26-083096.md) | not reported | not reported | [0.0 d](/filings/0001193125-26-419156.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: us-gaap:PaymentsOfDividendsCommonStock
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q1 FY2023 (2023-02-28) | Q2 FY2023 (2023-05-31) | Q3 FY2023 (2023-08-31) | Q1 FY2024 (2024-02-29) | Q2 FY2024 (2024-05-31) | Q3 FY2024 (2024-08-31) | Q1 FY2025 (2025-02-28) | Q2 FY2025 (2025-05-31) | Q3 FY2025 (2025-08-31) | Q1 FY2026 (2026-02-28) | Q2 FY2026 (2026-05-31) | Q3 FY2026 (2026-08-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | thousands of shares | [8,475](/filings/0000950170-24-044493.md) | [8,332](/filings/0000950170-24-083637.md) | [8,342](/filings/0000950170-24-114762.md) | [8,325](/filings/0000950170-25-053767.md) | [8,232](/filings/0000950170-25-095916.md) | [8,174](/filings/0001193125-25-240385.md) | [8,200](/filings/0001193125-26-155057.md) | [8,126](/filings/0001193125-26-304834.md) | [8,074](/filings/0001193125-26-419156.md) | [8,056](/filings/0001193125-26-155057.md) | [8,055](/filings/0001193125-26-304834.md) | [8,065](/filings/0001193125-26-419156.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 8,062,650 at 2026-10-08, from the cover of the [10-Q filed 2026-10-09](/filings/0001193125-26-419156.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:26 ET. No prices; not investment advice.